Guest Blog: Why Advocacy Tools Matter by Haley Magnetta

You want to make a difference, but advocacy can be confusing, frustrating, and time-consuming.  We can help. Sign up for Today’s Advocacy Tool – a month of inspiration, tips, and practical tools starting January 10. As a practicing Emergency Medicine Physician Assistant throughout the COVID-19 pandemic, I could not help but notice many areas where…

Read More

Sign up for daily tips on the Art and Craft of Advocacy

You want to make a difference, but advocacy can be confusing, frustrating, and time-consuming. We can help. Sign up for Today’s Advocacy Tool – a month of inspiration, tips, and practical tools. Every weekday for a month, we’ll send an email with insight, best practices, and lessons we’ve learned from the updated CT Health Advocacy…

Read More

ICER report on fair access to drugs prompts six insurers to change coverage policies

A powerful new scorecard from the Institute for Clinical and Economic Review (ICER) assessing 15 of the largest US formularies for barriers to accessing 28 fairly-priced drugs found generally good policies for clinical standards (96% are fair), step therapy (99%), and prescriber restrictions (100%). However, the report found poor policies for cost sharing tiers (77%)…

Read More

CTNJ Op-Ed – The Brainard Fund still making a difference after 64 years

In 2010, I got a call that advocates only dream about. The Hartford Foundation for Public Giving had a dedicated fund to pay medical bills for Hartford area residents who couldn’t afford them, and they wanted my help directing the money to people most in need. The good news is that the Brainard Fund still…

Read More

Last year unjustified price increases for nine drugs cost US healthcare $1.67 billion, Humira accounted for $1.4 billion

According to this year’s report, last year the US health system spent an extra $1.67 billion on price increases for nine drugs that were not supported by clinical evidence. Humira led this year’s list at $1.4 billion, accounting for 84% of US unjustified drug price increases in 2020. Humira aside, the more modest price increases…

Read More

Response to OHS primary care capitation defense

Today, the CT Health Policy Project responded to a letter from the Office of Health Strategy regarding concerns from 25 independent consumer advocates, providers, and organizations. OHS’s response to our offer to work together to improve the health of every Connecticut resident is very welcome. In that spirit, the letter clarifies a few misunderstandings of…

Read More

Cost Cap primary care project only focusing on raising spending, not services

At the October 26th Primary Care Subgroup meeting, in response to questioning by a member, the Office of Health Strategy’s (OHS) consultants repeatedly confirmed that the goal of the Cost Cap provision on primary care is solely to raise spending, not to increase services. Members raised serious concerns about sending more money into the current…

Read More

CT ranks 15th among states in healthcare affordability, but that’s not saying much

Connecticut has implemented many policies to make healthcare affordable; unfortunately, they aren’t working. According to Altarum’s new Healthcare Affordability State Policy Scorecard, Connecticut earned 43.1 out of 80 possible points. There is a lot of room for improvement. Altarum ranked states on adoption of policies that can impact affordability and on outcomes, whether care is…

Read More

Sign on letter voices deep concerns with primary care capitation

Today twenty-five independent advocates and providers signed a letter to the Office of Health Strategy opposing capitation of primary care services across Connecticut. The letter shares serious concerns with the Office of Health Strategy’s (OHS) plan to shift all primary care in Connecticut to a capitated payment model. The current concerns echo advocates’ and legislators’…

Read More

Connecticut hospital systems vary in reducing low-value care

A new report published in JAMA Internal Medicine on low-value care provided to Medicare beneficiaries at the health system level offers actionable tools to improve effective care on the ground. Healthcare services that provide little or no health benefit, may harm patients, increase costs, and waste resources are low-value. Examples include prostate specific antigen testing…

Read More